8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Apr 2, 2026·SEC
Becton, Dickinson and Company(BDX)Earnings, Financials & Key Ratios
BDX•NYSE
$144.76
$52.45B mkt cap·24.8× P/E·Price updated May 6, 2026
AboutBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.Show more
- Revenue$21.84B+8.2%
- EBITDA$5.04B+7.6%
- Net Income$1.68B-1.6%
- EPS (Diluted)5.83-0.5%
- Gross Margin45.44%+0.5%
- EBITDA Margin23.08%-0.6%
- Operating Margin11.8%-0.6%
- Net Margin7.68%-9.1%
- ROE6.54%-0.8%
- ROIC4.33%+4.5%
- Debt/Equity0.76-9.4%
- Interest Coverage4.07-15.2%
BDX Key Insights
Becton, Dickinson and Company (BDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.9%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BDX Price & Volume
Becton, Dickinson and Company (BDX) stock price & volume — 10-year historical chart
Loading chart...
BDX Growth Metrics
Becton, Dickinson and Company (BDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.82%
5 Years6.32%
3 Years4.99%
TTM6.22%
Profit CAGR
10 Years9.21%
5 Years13.93%
3 Years-1.93%
TTM1.74%
EPS CAGR
10 Years5.7%
5 Years16.56%
3 Years-0.28%
TTM1.83%
Return on Capital
10 Years4.62%
5 Years4.95%
3 Years5.04%
Last Year5.41%
BDX Recent Earnings
Becton, Dickinson and Company (BDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 9, 2026EPS
$2.91
Est $2.21
+31.7%
Revenue
$4.5B
Est $5.1B
-12.8%
Q4 2025
Nov 6, 2025EPS
$3.96
Est $3.92
+1.0%
Revenue
$5.9B
Est $5.9B
-0.3%
Q3 2025
Aug 7, 2025EPS
$3.68
Est $3.40
+8.2%
Revenue
$5.5B
Est $5.5B
+0.4%
Q2 2025
May 1, 2025EPS
$3.35
Est $3.28
+2.1%
Revenue
$5.3B
Est $5.4B
-1.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 9, 2026 | $2.91vs $2.21+31.7% | $4.5Bvs $5.1B-12.8% |
| Q4 2025 | Nov 6, 2025 | $3.96vs $3.92+1.0% | $5.9Bvs $5.9B-0.3% |
| Q3 2025 | Aug 7, 2025 | $3.68vs $3.40+8.2% | $5.5Bvs $5.5B+0.4% |
| Q2 2025 | May 1, 2025 | $3.35vs $3.28+2.1% | $5.3Bvs $5.4B-1.5% |
Based on last 12 quarters of dataView full earnings history →
BDX Peer Comparison
Becton, Dickinson and Company (BDX) competitors in Drug delivery and infusion consumables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BAX | 8.77B | 16.98 | -9.70 | 5.72% | -9.7% | -16.5% | 1.64 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 SYK | 111.96B | 292.33 | 34.80 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 16.22B | 82.83 | 23.33 | 7.2% | 9.05% | 5.77% | 0.59 | |
 EW | 47.97B | 83.20 | 45.46 | 11.55% | 17.64% | 10.35% | 0.07 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 DHR | 123.8B | 174.92 | 34.71 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BDX vs Peers
Becton, Dickinson and Company (BDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDX Income Statement
Becton, Dickinson and Company (BDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 12.09B | 15.98B | 17.29B | 16.07B | 19.13B | 18.87B | 19.37B | 20.18B | 21.84B | 21.92B |
| Revenue Growth % | -3.12% | 32.17% | 8.18% | -7.03% | 19.02% | -1.36% | 2.66% | 4.16% | 8.23% | 6.22% |
| Cost of Goods Sold | 6.13B | 8.71B | 9B | 9.28B | 10.5B | 10.39B | 11.2B | 11.05B | 11.91B | 11.89B |
| COGS % of Revenue | 50.67% | 54.52% | 52.06% | 57.71% | 54.88% | 55.08% | 57.83% | 54.78% | 54.56% | - |
| Gross Profit | 5.96B▲ 0% | 7.27B▲ 21.9% | 8.29B▲ 14.0% | 6.8B▼ 18.0% | 8.63B▲ 27.0% | 8.48B▼ 1.8% | 8.17B▼ 3.6% | 9.13B▲ 11.7% | 9.92B▲ 8.8% | 10.03B▲ 0% |
| Gross Margin % | 49.33% | 45.48% | 47.94% | 42.29% | 45.12% | 44.92% | 42.17% | 45.22% | 45.44% | 45.76% |
| Gross Profit Growth % | -0.43% | 21.86% | 14.02% | -17.98% | 26.96% | -1.78% | -3.62% | 11.69% | 8.76% | - |
| Operating Expenses | 4.44B | 5.76B | 6.53B | 5.89B | 6.38B | 6.2B | 6.06B | 6.73B | 7.35B | 7.32B |
| OpEx % of Revenue | 36.74% | 36.04% | 37.76% | 36.62% | 33.35% | 32.83% | 31.28% | 33.34% | 33.64% | - |
| Selling, General & Admin | 2.91B | 4.02B | 4.33B | 4.18B | 4.72B | 4.71B | 4.72B | 4.86B | 5.28B | 5.39B |
| SG&A % of Revenue | 24.06% | 25.13% | 25.05% | 26.04% | 24.67% | 24.95% | 24.36% | 24.07% | 24.16% | - |
| Research & Development | 770M | 1B | 1.06B | 1.04B | 1.28B | 1.26B | 1.24B | 1.19B | 1.26B | 1.24B |
| R&D % of Revenue | 6.37% | 6.28% | 6.14% | 6.46% | 6.69% | 6.66% | 6.39% | 5.9% | 5.79% | - |
| Other Operating Expenses | 764M | 740M | 1.13B | 662M | 383M | 230M | 103M | 681M | 806M | 3M |
| Operating Income | 1.52B▲ 0% | 1.51B▼ 0.9% | 1.76B▲ 16.6% | 912M▼ 48.2% | 2.25B▲ 146.7% | 2.28B▲ 1.4% | 2.11B▼ 7.5% | 2.4B▲ 13.5% | 2.58B▲ 7.6% | 2.72B▲ 0% |
| Operating Margin % | 12.59% | 9.44% | 10.18% | 5.67% | 11.76% | 12.09% | 10.9% | 11.88% | 11.8% | 12.4% |
| Operating Income Growth % | 6.43% | -0.85% | 16.63% | -48.18% | 146.71% | 1.42% | -7.49% | 13.55% | 7.55% | - |
| EBITDA | 2.61B | 3.49B | 4.01B | 3.03B | 4.48B | 4.51B | 4.4B | 4.68B | 5.04B | 5.19B |
| EBITDA Margin % | 21.58% | 21.82% | 23.21% | 18.83% | 23.42% | 23.91% | 22.71% | 23.21% | 23.08% | 23.66% |
| EBITDA Growth % | 2.59% | 33.6% | 15.08% | -24.57% | 48% | 0.69% | -2.48% | 6.46% | 7.62% | 9.38% |
| D&A (Non-Cash Add-back) | 1.09B | 1.98B | 2.25B | 2.12B | 2.23B | 2.23B | 2.29B | 2.29B | 2.46B | 2.47B |
| EBIT | 1.5B | 1.88B | 1.81B | 942M | 2.16B | 2.18B | 2.11B | 2.53B | 2.5B | 2.63B |
| Net Interest Income | -445M | -641M | -627M | -521M | -460M | -382M | -403M | -365M | -575M | -546M |
| Interest Income | 76M | 65M | 12M | 7M | 9M | 16M | 49M | 163M | 38M | 19M |
| Interest Expense | 521M | 706M | 639M | 528M | 469M | 398M | 452M | 528M | 613M | 565M |
| Other Income/Expense | -546M | -336M | -584M | -498M | -558M | -499M | -449M | -392M | -696M | -656M |
| Pretax Income | 976M▲ 0% | 1.17B▲ 20.2% | 1.18B▲ 0.3% | 414M▼ 64.8% | 1.69B▲ 308.7% | 1.78B▲ 5.4% | 1.66B▼ 6.8% | 2B▲ 20.6% | 1.88B▼ 6.1% | 2.06B▲ 0% |
| Pretax Margin % | 8.07% | 7.34% | 6.8% | 2.58% | 8.84% | 9.45% | 8.58% | 9.94% | 8.62% | 9.41% |
| Income Tax | -124M | 862M | -57M | 62M | 88M | 148M | 132M | 300M | 204M | 306M |
| Effective Tax Rate % | -12.7% | 73.49% | -4.85% | 14.98% | 5.2% | 8.3% | 7.94% | 14.96% | 10.84% | 14.83% |
| Net Income | 1.1B▲ 0% | 311M▼ 71.7% | 1.23B▲ 296.5% | 874M▼ 29.1% | 2.09B▲ 139.4% | 1.78B▼ 15.0% | 1.48B▼ 16.6% | 1.71B▲ 14.9% | 1.68B▼ 1.6% | 1.76B▲ 0% |
| Net Margin % | 9.1% | 1.95% | 7.13% | 5.44% | 10.94% | 9.43% | 7.66% | 8.45% | 7.68% | 8.01% |
| Net Income Growth % | 12.7% | -71.73% | 296.46% | -29.12% | 139.36% | -14.96% | -16.58% | 14.89% | -1.58% | 1.74% |
| Net Income (Continuing) | 1.1B | 311M | 1.23B | 352M | 1.6B | 1.64B | 1.53B | 1.71B | 1.68B | 1.76B |
| Discontinued Operations | 0 | 0 | 0 | 522M | 488M | 144M | -46M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 4.60▲ 0% | 0.60▼ 87.0% | 3.89▲ 548.3% | 2.71▼ 30.3% | 6.85▲ 152.8% | 5.88▼ 14.2% | 4.94▼ 16.0% | 5.86▲ 18.6% | 5.83▼ 0.5% | 6.16▲ 0% |
| EPS Growth % | 2.45% | -86.96% | 548.33% | -30.33% | 152.77% | -14.16% | -15.99% | 18.62% | -0.51% | 1.83% |
| EPS (Basic) | 4.70 | 0.62 | 3.96 | 2.75 | 6.92 | 5.93 | 4.97 | 5.88 | 5.84 | - |
| Diluted Shares Outstanding | 223.59M | 264.62M | 274.77M | 282.4M | 292.09M | 287.36M | 288.39M | 291.01M | 287.12M | 285.07M |
| Basic Shares Outstanding | 218.94M | 258.35M | 269.94M | 278.97M | 289.29M | 285M | 286.28M | 289.76M | 286.61M | 285.07M |
| Dividend Payout Ratio | 61.55% | 298.07% | 79.81% | 117.39% | 50.1% | 60.82% | 75.07% | 64.52% | 71.28% | - |
BDX Balance Sheet
Becton, Dickinson and Company (BDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 18.63B | 7.41B | 6.64B | 8.97B | 8.84B | 8.14B | 8.68B | 10.47B | 9.26B | 9.19B |
| Cash & Short-Term Investments | 14.22B | 1.16B | 566M | 2.85B | 2.4B | 1.17B | 1.42B | 2.3B | 859M | 1.03B |
| Cash Only | 14.18B | 1.14B | 536M | 2.83B | 2.39B | 1.16B | 1.42B | 1.86B | 851M | 1.02B |
| Short-Term Investments | 37M | 17M | 30M | 20M | 12M | 8M | 8M | 445M | 8M | 11M |
| Accounts Receivable | 1.74B | 2.32B | 2.35B | 2.4B | 2.35B | 2.19B | 2.53B | 3.03B | 2.99B | 2.51B |
| Days Sales Outstanding | 52.64 | 52.96 | 49.5 | 54.45 | 44.84 | 42.38 | 47.74 | 54.86 | 50.04 | 47.76 |
| Inventory | 1.82B | 2.45B | 2.58B | 2.74B | 2.74B | 3.22B | 3.27B | 3.84B | 3.89B | 4.08B |
| Days Inventory Outstanding | 108.28 | 102.66 | 104.57 | 107.93 | 95.35 | 113.23 | 106.65 | 126.91 | 119.29 | 120.11 |
| Other Current Assets | 0 | 233M | 55M | 92M | 1.34B | 1.56B | 1.45B | 1.29B | 1.51B | 1.56B |
| Total Non-Current Assets | 19.1B | 46.49B | 45.1B | 45.04B | 45.04B | 44.79B | 44.1B | 46.82B | 46.07B | 45.65B |
| Property, Plant & Equipment | 4.64B | 5.38B | 5.66B | 5.92B | 6B | 6.01B | 6.56B | 6.82B | 7B | 6.97B |
| Fixed Asset Turnover | 2.61x | 2.97x | 3.06x | 2.71x | 3.19x | 3.14x | 2.95x | 2.96x | 3.12x | 3.20x |
| Goodwill | 7.56B | 23.6B | 23.38B | 23.62B | 23.89B | 24.62B | 24.52B | 26.46B | 33.02B | 26.62B |
| Intangible Assets | 5.89B | 16.44B | 14.98B | 13.81B | 12.78B | 12.31B | 10.95B | 10.92B | 2.99B | 9.03B |
| Long-Term Investments | 38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 969M | 1.08B | 1.09B | 1.69B | 2.37B | 1.85B | 2.08B | 2.62B | 3.06B | 11.37B |
| Total Assets | 37.73B▲ 0% | 53.9B▲ 42.9% | 51.84B▼ 3.8% | 54.01B▲ 4.2% | 53.88B▼ 0.2% | 52.93B▼ 1.8% | 52.78B▼ 0.3% | 57.29B▲ 8.5% | 55.33B▼ 3.4% | 54.84B▲ 0% |
| Asset Turnover | 0.32x | 0.30x | 0.33x | 0.30x | 0.36x | 0.36x | 0.37x | 0.35x | 0.39x | 0.40x |
| Asset Growth % | 47.48% | 42.85% | -3.83% | 4.19% | -0.24% | -1.76% | -0.29% | 8.54% | -3.42% | -3.75% |
| Total Current Liabilities | 3.34B | 7.22B | 5.66B | 5.84B | 6.63B | 7.81B | 6.64B | 8.96B | 8.31B | 8.76B |
| Accounts Payable | 797M | 1.11B | 1.09B | 1.35B | 1.74B | 1.7B | 1.64B | 1.9B | 1.97B | 6.14B |
| Days Payables Outstanding | 47.47 | 46.33 | 44.28 | 53.32 | 60.45 | 59.67 | 53.47 | 62.61 | 60.47 | 157.7 |
| Short-Term Debt | 203M | 2.6B | 1.31B | 706M | 626M | 2.3B | 1.26B | 2.31B | 1.56B | 2.62B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1M | 0 | 0 | 2.9B | 2.49B | 2.49B | 3.33B | 4.45B | 0 |
| Current Ratio | 5.58x | 1.03x | 1.17x | 1.54x | 1.33x | 1.04x | 1.31x | 1.17x | 1.11x | 1.11x |
| Quick Ratio | 5.03x | 0.69x | 0.72x | 1.07x | 0.92x | 0.63x | 0.81x | 0.74x | 0.64x | 0.64x |
| Cash Conversion Cycle | 113.45 | 109.3 | 109.8 | 109.07 | 79.74 | 95.94 | 100.92 | 119.16 | 108.86 | 10.17 |
| Total Non-Current Liabilities | 21.44B | 25.69B | 25.03B | 24.41B | 23.56B | 19.84B | 20.34B | 22.44B | 21.62B | 20.8B |
| Long-Term Debt | 18.67B | 18.89B | 18.08B | 17.22B | 17.45B | 14.27B | 15.15B | 18.61B | 17.62B | 16.92B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 344M | 384M | 414M | 667M | 0 | 0 |
| Deferred Tax Liabilities | 1.61B | 5.74B | 5.68B | 5.75B | 2.68B | 2.67B | 2.45B | 2.07B | 0 | 0 |
| Other Non-Current Liabilities | 1.17B | 1.06B | 1.27B | 1.43B | 3.08B | 2.51B | 2.33B | 1.1B | 4B | 15.49B |
| Total Liabilities | 24.79B | 32.91B | 30.68B | 30.25B | 30.2B | 27.65B | 26.98B | 31.4B | 29.94B | 29.56B |
| Total Debt | 18.87B | 21.5B | 19.39B | 17.93B | 18.42B | 16.95B | 16.82B | 21.59B | 19.18B | 19.54B |
| Net Debt | 4.69B | 20.36B | 18.85B | 15.11B | 16.03B | 15.79B | 15.34B | 19.73B | 18.33B | 18.52B |
| Debt / Equity | 1.46x | 1.02x | 0.92x | 0.75x | 0.78x | 0.67x | 0.65x | 0.83x | 0.76x | 0.76x |
| Debt / EBITDA | 7.23x | 6.16x | 4.83x | 5.92x | 4.11x | 3.76x | 3.82x | 4.61x | 3.81x | 3.77x |
| Net Debt / EBITDA | 1.80x | 5.84x | 4.70x | 4.99x | 3.58x | 3.50x | 3.49x | 4.21x | 3.64x | 3.64x |
| Interest Coverage | 2.87x | 2.66x | 2.84x | 1.78x | 4.61x | 5.48x | 4.68x | 4.80x | 4.07x | 4.65x |
| Total Equity | 12.95B▲ 0% | 20.99B▲ 62.1% | 21.08B▲ 0.4% | 23.77B▲ 12.7% | 23.68B▼ 0.4% | 25.28B▲ 6.8% | 25.8B▲ 2.0% | 25.89B▲ 0.4% | 25.39B▼ 1.9% | 25.28B▲ 0% |
| Equity Growth % | 69.61% | 62.14% | 0.42% | 12.73% | -0.37% | 6.78% | 2.04% | 0.36% | -1.93% | -4.74% |
| Book Value per Share | 57.91 | 79.34 | 76.72 | 84.15 | 81.06 | 87.98 | 89.45 | 88.96 | 88.43 | 88.69 |
| Total Shareholders' Equity | 12.95B | 20.99B | 21.08B | 23.77B | 23.68B | 25.28B | 25.8B | 25.89B | 25.39B | 25.28B |
| Common Stock | 347M | 347M | 347M | 365M | 365M | 365M | 371M | 371M | 371M | 371M |
| Retained Earnings | 13.11B | 12.59B | 12.91B | 12.79B | 13.83B | 15.16B | 15.54B | 16.14B | 16.62B | 16.7B |
| Treasury Stock | -8.43B | -6.24B | -6.19B | -6.14B | -7.72B | -8.33B | -8.3B | -8.81B | -9.81B | -10.06B |
| Accumulated OCI | -1.72B | -1.91B | -2.28B | -2.55B | -2.09B | -1.49B | -1.55B | -1.73B | -1.87B | -1.83B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDX Cash Flow Statement
Becton, Dickinson and Company (BDX) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 2.55B | 2.87B | 3.33B | 3.54B | 4.65B | 2.63B | 2.99B | 3.8B | 3.43B | 3.43B |
| Operating CF Margin % | 21.09% | 17.93% | 19.26% | 22.02% | 24.29% | 13.95% | 15.43% | 18.82% | 15.71% | - |
| Operating CF Growth % | -0.35% | 12.35% | 16.23% | 6.28% | 31.31% | -43.34% | 13.52% | 27.07% | -9.69% | -61.97% |
| Net Income | 1.1B | 311M | 1.22B | 874M | 2.09B | 1.78B | 1.53B | 1.71B | 1.68B | 1.76B |
| Depreciation & Amortization | 1.09B | 1.98B | 2.25B | 2.15B | 2.27B | 2.23B | 2.29B | 2.29B | 2.46B | 2.47B |
| Stock-Based Compensation | 174M | 322M | 261M | 236M | 229M | 233M | 259M | 247M | 258M | -35M |
| Deferred Taxes | -236M | -240M | -381M | -302M | -304M | -120M | -622M | -211M | -474M | 112M |
| Other Non-Cash Items | 795M | -403M | 120M | 65M | 75M | -94M | 164M | -522M | 306M | -64M |
| Working Capital Changes | -371M | 897M | -143M | 512M | 282M | -1.39B | -630M | 293M | -800M | -845M |
| Change in Receivables | -93M | -170M | -51M | -48M | -95M | 32M | -290M | -453M | 71M | 0 |
| Change in Inventory | -46M | 246M | -149M | -125M | -104M | -631M | -15M | 98M | -410M | 0 |
| Change in Payables | 134M | 867M | -470M | 205M | 687M | -473M | -517M | 625M | -185M | 0 |
| Cash from Investing | -883M | -15.83B | -741M | -1.23B | -1.88B | -3.23B | -716M | -5.51B | -818M | -1.21B |
| Capital Expenditures | -727M | -895M | -957M | -810M | -1.23B | -973M | -874M | -725M | -760M | -763M |
| CapEx % of Revenue | 6.01% | 5.6% | 5.54% | 5.04% | 6.43% | 5.16% | 4.51% | 3.59% | 3.48% | - |
| Acquisitions | -9M | -14.75B | 477M | -164M | -508M | -2.07B | 540M | -3.92B | 0 | 8M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -887M | -1.09B | -261M | -258M | -141M | -188M | -382M | -444M | -480M | 377M |
| Cash from Financing | 10.98B | -57M | -3.22B | 22M | -3.31B | -591M | -1.96B | 2.09B | -3.62B | -1.99B |
| Debt Issued (Net) | 7.28B | 1.09B | -2.04B | -1.76B | -243M | -78M | -722M | 3.77B | -1.33B | -217M |
| Equity Issued (Net) | 4.61B | 0 | 0 | 2.92B | -1.75B | -500M | 0 | -500M | -1B | -500M |
| Dividends Paid | -677M | -927M | -984M | -1.03B | -1.05B | -1.08B | -1.11B | -1.1B | -1.2B | -1.19B |
| Share Repurchases | -220M | 0 | 0 | 0 | -1.75B | -500M | 0 | -500M | -1B | -500M |
| Other Financing | -234M | -220M | -204M | -109M | -265M | 1.07B | -121M | -88M | -87M | -81M |
| Net Change in Cash | 12.64B▲ 0% | -13.04B▼ 203.2% | -646M▲ 95.0% | 2.33B▲ 460.2% | -525M▼ 122.6% | -1.23B▼ 134.9% | 322M▲ 126.1% | 375M▲ 16.5% | -1B▼ 368.0% | 210M▲ 0% |
| Free Cash Flow | 1.82B▲ 0% | 1.97B▲ 8.1% | 2.37B▲ 20.5% | 2.73B▲ 15.0% | 3.42B▲ 25.2% | 1.66B▼ 51.4% | 2.12B▲ 27.4% | 3.07B▲ 45.2% | 2.67B▼ 13.1% | 2.63B▲ 0% |
| FCF Margin % | 15.07% | 12.33% | 13.72% | 16.98% | 17.86% | 8.8% | 10.92% | 15.22% | 12.23% | 12% |
| FCF Growth % | -0.98% | 8.06% | 20.46% | 15% | 25.17% | -51.41% | 27.41% | 45.25% | -13.09% | -10.39% |
| FCF per Share | 8.15 | 7.44 | 8.64 | 9.66 | 11.70 | 5.78 | 7.33 | 10.56 | 9.30 | 9.30 |
| FCF Conversion (FCF/Net Income) | 2.32x | 9.21x | 2.70x | 4.05x | 2.22x | 1.48x | 2.01x | 2.23x | 2.04x | 1.50x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDX Key Ratios
Becton, Dickinson and Company (BDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 10.69% | 1.83% | 5.86% | 3.9% | 8.82% | 7.27% | 5.81% | 6.6% | 6.54% | 6.93% |
| Return on Invested Capital (ROIC) | 6.47% | 3.84% | 3.25% | 1.74% | 4.29% | 4.24% | 3.85% | 4.14% | 4.33% | 4.33% |
| Gross Margin | 49.33% | 45.48% | 47.94% | 42.29% | 45.12% | 44.92% | 42.17% | 45.22% | 45.44% | 45.76% |
| Net Margin | 9.1% | 1.95% | 7.13% | 5.44% | 10.94% | 9.43% | 7.66% | 8.45% | 7.68% | 8.01% |
| Debt / Equity | 1.46x | 1.02x | 0.92x | 0.75x | 0.78x | 0.67x | 0.65x | 0.83x | 0.76x | 0.76x |
| Interest Coverage | 2.87x | 2.66x | 2.84x | 1.78x | 4.61x | 5.48x | 4.68x | 4.80x | 4.07x | 4.65x |
| FCF Conversion | 2.32x | 9.21x | 2.70x | 4.05x | 2.22x | 1.48x | 2.01x | 2.23x | 2.04x | 1.50x |
| Revenue Growth | -3.12% | 32.17% | 8.18% | -7.03% | 19.02% | -1.36% | 2.66% | 4.16% | 8.23% | 6.22% |
BDX SEC Filings & Documents
Becton, Dickinson and Company (BDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BDX Frequently Asked Questions
Becton, Dickinson and Company (BDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Becton, Dickinson and Company (BDX) reported $21.92B in revenue for fiscal year 2025. This represents a 692% increase from $2.77B in 1996.
Becton, Dickinson and Company (BDX) grew revenue by 8.2% over the past year. This is steady growth.
Yes, Becton, Dickinson and Company (BDX) is profitable, generating $1.76B in net income for fiscal year 2025 (7.7% net margin).
Dividend & Returns
Yes, Becton, Dickinson and Company (BDX) pays a dividend with a yield of 2.88%. This makes it attractive for income-focused investors.
Becton, Dickinson and Company (BDX) has a return on equity (ROE) of 6.5%. This is below average, suggesting room for improvement.
Becton, Dickinson and Company (BDX) generated $2.63B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More BDX
Becton, Dickinson and Company (BDX) financial analysis — history, returns, DCA and operating performance tools
Full BDX Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates